Apelin‐13 Protects Against Myocardial Hypoxia/Reoxygenation (H/R) Injury by Inhibiting Ferroptosis Via Nrf2 Activation
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Fan Liang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Ferroptosis, Myocardial Reperfusion Injury, Myocytes, Cardiac. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: This study was supported by the "Natural Science Foundation of Heilongjiang Province (No. LH2022H071)" and the "Innovative Research Project for Graduate Studen….
Abstract (Originalsprache)
Ischemia‐reperfusion (IR)‐induced myocardial damage represents a major pathological event in coronary artery disease (CAD). Effective therapeutic strategies are urgently needed to improve clinical outcomes for CAD patients. Apelin‐13, primarily produced by magnocellular neurons, exhibits diverse biological functions across various cell types and tissues. However, its role in myocardial IR injury remains unexplored. In this study, we utilized an in vitro model of myocardial IR injury using H9c2 cardiomyocytes to investigate the potential protective effects of Apelin‐13. Our findings reveal that Apelin‐13 protects against hypoxia/reoxygenation (H/R)‐induced oxidative stress in H9c2 cells by reducing mitochondrial reactive oxygen species (ROS) and malondialdehyde (MDA) levels, while enhancing superoxide dismutase (SOD) activity. Additionally, Apelin‐13 alleviates H/R‐induced mitochondrial dysfunction, as evidenced by increased mitochondrial membrane potential (MMP) and adenosine triphosphate (ATP) production. Crucially, Apelin‐13 mitigates H/R‐induced cardiomyocyte injury, as shown by reduced levels of creatine kinase‐myocardial band (CK‐MB), cardiac troponin I (cTnI), and lactate dehydrogenase (LDH). Remarkably, Apelin‐13 also counteracts ferroptosis during H/R by decreasing ferrous iron (Fe²⁺) concentrations, increasing glutathione (GSH) levels, and suppressing glutathione peroxidase 4 (GPX4) and ferritin heavy chain 1 (FTH1) expression. These protective actions were negated by the ferroptosis inducer Erastin. Further investigation revealed that Apelin‐13 activates the transcription factor nuclear factor erythroid 2‐related factor 2 (Nrf2) through enhanced nuclear translocation and upregulation of heme oxygenase‐1 (HO‐1). Conversely, Nrf2 knockdown nullified the protective effects of Apelin‐13 against ferroptosis and cardiomyocyte injury, underscoring the critical involvement of Nrf2 in mediating these benefits. Collectively, our results highlight the promising therapeutic potential of Apelin‐13 in managing CAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Förderung
- This study was supported by the "Natural Science Foundation of Heilongjiang Province (No. LH2022H071)" and the "Innovative Research Project for Graduate Studen…
Zitieren
APA
Liang, F., Li, C., Liu, Y., & Sui, Y. (2025). Apelin‐13 Protects Against Myocardial Hypoxia/Reoxygenation (H/R) Injury by Inhibiting Ferroptosis Via Nrf2 Activation. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70223
Vancouver
Liang F, Li C, Liu Y, Sui Y. Apelin‐13 Protects Against Myocardial Hypoxia/Reoxygenation (H/R) Injury by Inhibiting Ferroptosis Via Nrf2 Activation. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70223
BibTeX
@article{Liang2025,
author = {Liang, Fan and Li, Chen and Liu, Yumiao and Sui, Yanbo},
title = {Apelin‐13 Protects Against Myocardial Hypoxia/Reoxygenation (H/R) Injury by Inhibiting Ferroptosis Via Nrf2 Activation},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70223}
}
EUVIMED